Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon‐ineligible/intolerant individuals

Treatment guidance for chronic hepatitis C (CHC) released by the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) offers two options for interferon (IFN)‐ineligible/intolerant individuals with genotype 1 infection: sofosbuvir/ribavirin (SOF/RBV) for 24 weeks or sofosbuvir/simeprevir (SOF/SMV) for 12 weeks. A 24‐week course of SOF/RBV costs approximately US$169,000, with sustained virologic response (SVR) rates ranging from 52% to 84%; 12 weeks of SOF/SMV costs approximately $150,000, with SVR between 89% and 100%. Because SOF/SMV is currently used off‐label, debate exists among physicians and payers about whether it should be prescribed and covered. This article presents a cost‐effectiveness analysis of these two treatment regimens accounting for costs of drugs, treatment‐related medical care, retreatment for individuals who do not achieve SVR, and natural history of continued HCV infection after failed retreatment. Analysis uses a Markov model with a lifetime horizon and a societal perspective. In the base‐case scenario, SOF/SMV dominated SOF/RBV in a modeled 50‐year‐old cohort of treatment‐naïve and ‐experienced subjects, excluding those who failed earlier therapy with telaprevir or boceprevir. SOF/SMV yielded lower costs and more quality‐adjusted life years (QALYs) for the average subject, compared to SOF/RBV ($165,336 and 14.69 QALYs vs. $243,586 and 14.45 QALYs, respectively). In base‐case cost analysis, the SOF/SMV treatment strategy saved $91,590 per SVR, compared to SOF/RBV. Under all one‐way sensitivity scenarios, SOF/SMV remained dominant and resulted in cost savings. Conclusions: These results suggest that a 12‐week course of SOF/SMV is a more cost‐effective treatment for genotype 1 CHC than 24 weeks of SOF/RBV among IFN‐ineligible/intolerant individuals, supporting the AASLD/IDSA guidance and offering implications for both clinical and regulatory decision making as well as pharmaceutical pricing. (Hepatology 2014;60:37–45)

[1]  N. Shire,et al.  Distribution of hepatitis C virus genotypes in a diverse US integrated health care population , 2012, Journal of medical virology.

[2]  P. Hewson,et al.  Surveillance of cirrhosis for hepatocellular carcinoma: a cost–utility analysis , 2008, British Journal of Cancer.

[3]  Z. Younossi,et al.  Cost effectiveness of interferon α2b combined with ribavirin for the treatment of chronic hepatitis C , 1999, Hepatology.

[4]  A. Sonnenberg,et al.  Survival and cost‐effectiveness analysis of competing strategies in the management of small hepatocellular carcinoma , 2010, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[5]  G. Dore,et al.  Sa2072 Simeprevir (TMC435) With Peginterferon/Ribavirin for Chronic HCV Genotype-1 Infection in Treatment-Nai;auve Patients: Results From QUEST-1, a Phase III Trial , 2013 .

[6]  T. Asselah,et al.  HCV direct‐acting antiviral agents: the best interferon‐free combinations , 2014, Liver international : official journal of the International Association for the Study of the Liver.

[7]  M. Manns,et al.  1413 SIMEPREVIR (TMC435) WITH PEGINTERFERON/RIBAVIRIN FOR TREATMENT OF CHRONIC HCV GENOTYPE-1 INFECTION IN TREATMENT-NAÏVE PATIENTS: RESULTS FROM QUEST-2, A PHASE III TRIAL , 2013 .

[8]  S. Saab,et al.  The effects of hepatitis C recurrence on health‐related quality of life in liver transplant recipients , 2010, Liver international : official journal of the International Association for the Study of the Liver.

[9]  G. Dore,et al.  Estimation of stage‐specific fibrosis progression rates in chronic hepatitis C virus infection: A meta‐analysis and meta‐regression , 2008, Hepatology.

[10]  E. Bini,et al.  Prospective Multicenter Study of Eligibility for Antiviral Therapy Among 4,084 U.S. Veterans with Chronic Hepatitis C Virus Infection , 2005, The American Journal of Gastroenterology.

[11]  Brad J. Wood,et al.  Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. , 2013, JAMA.

[12]  R. Groszmann,et al.  American association for the study of liver diseases , 1992 .

[13]  F. Carnot,et al.  Reversibility of hepatitis C virus-related cirrhosis. , 2004, Human pathology.

[14]  R. Wiesner,et al.  Resource utilization in liver transplantation: effects of patient characteristics and clinical practice. NIDDK Liver Transplantation Database Group. , 1999, JAMA.

[15]  M. Alter,et al.  The Prevalence of Hepatitis C Virus Infection in the United States, 1999 through 2002 , 2006, Annals of Internal Medicine.

[16]  G. Kukolj,et al.  Baseline Hepatitis C Virus (HCV) NS3 Polymorphisms and Their Impact on Treatment Response in Clinical Studies of the HCV NS3 Protease Inhibitor Faldaprevir , 2013, Antimicrobial Agents and Chemotherapy.

[17]  J B Wong,et al.  Estimates of the Cost-Effectiveness of a Single Course of Interferon-2b in Patients with Histologically Mild Chronic Hepatitis C , 1997, Annals of Internal Medicine.

[18]  P. Nyckowski,et al.  Liver transplantation in hepatitis C virus-related cirrhosis. , 2003, Transplantation proceedings.

[19]  D. Owens,et al.  New Protease Inhibitors for the Treatment of Chronic Hepatitis C: A Cost-Effectiveness Analysis Author Names , 2012 .

[20]  S. El-Kamary,et al.  All-cause, liver-related, and non-liver-related mortality among HCV-infected individuals in the general US population. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  H. Mo,et al.  Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial , 2014, The Lancet.

[22]  A. Chiesa,et al.  Predicting Mortality Risk in Patients With Compensated HCV-Induced Cirrhosis: A Long-Term Prospective Study , 2009, The American Journal of Gastroenterology.

[23]  S. Pol,et al.  Brief Communication: The Relationship of Regression of Cirrhosis to Outcome in Chronic Hepatitis C , 2008, Annals of Internal Medicine.

[24]  J. Emparanza,et al.  [The prevalence of hepatitis C virus infection]. , 1998, Gastroenterologia y hepatologia.

[25]  Brian L. Pearlman,et al.  Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[26]  B. Luxon,et al.  Limited success of HCV antiviral therapy in United States veterans , 2002, American Journal of Gastroenterology.

[27]  E L Murphy,et al.  Prevalence of hepatitis C virus infection in the United States. , 1999, The New England journal of medicine.

[28]  J. Kaldor,et al.  Estimation of Utilities for Chronic Hepatitis C from SF-36 Scores , 2005, The American Journal of Gastroenterology.

[29]  A. Bhalla,et al.  Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. , 1997, Gastroenterology.

[30]  M. Manns,et al.  Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. , 2002, Gastroenterology.

[31]  A. Burroughs,et al.  Assessing health‐related quality of life pre– and post–liver transplantation: A prospective multicenter study , 2002, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[32]  R. Schinazi,et al.  All‐oral, interferon‐free treatment for chronic hepatitis C: cost‐effectiveness analyses , 2013, Journal of viral hepatitis.

[33]  M. Golden,et al.  Cost-effectiveness and population outcomes of general population screening for hepatitis C. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[34]  William M. Lee,et al.  A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C , 2011, Hepatology.

[35]  S. Saab,et al.  Timing of hepatitis C antiviral therapy in patients with advanced liver disease: A decision analysis model , 2010, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[36]  T. Asselah,et al.  Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. , 2008, Gastroenterology.

[37]  G. Dore,et al.  PostersLate-Breaker Poster Abstracts1425 SIMEPREVIR (TMC435) WITH PEGINTERFERON/RIBAVIRIN FOR CHRONIC HCV GENOTYPE-1 INFECTION IN TREATMENT-NAÏVE PATIENTS: RESULTS FROM QUEST-1, A PHASE III TRIAL , 2013 .

[38]  P. Terasaki,et al.  Liver transplantation in the United States. , 2005, Clinical transplants.

[39]  H. Mo,et al.  Susceptibility of Treatment-Naive Hepatitis C Virus (HCV) Clinical Isolates to HCV Protease Inhibitors , 2010, Antimicrobial Agents and Chemotherapy.

[40]  O. Weiland,et al.  Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy , 2004, Gut.

[41]  J J Fung,et al.  Liver Transplantation in the United States, 1999–2008 , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[42]  Brian L. Pearlman,et al.  svr results of a once-daily regimen of simeprevir (tmc435) plus sofosbuvir (gs-7977) with or without ribavirin in cirrhotic and non-cirrhotic Hcv genotype 1 treatment-naïve and prior null responder patients: The Cosmos study : lb-3 , 2013 .

[43]  D. Nelson,et al.  845 ONCE DAILY SOFOSBUVIR PLUS RIBAVIRIN FOR 12 AND 24 WEEKS IN TREATMENT-NAÏVE PATIENTS WITH HCV INFECTION: THE QUANTUM STUDY , 2013 .